U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07180160) titled 'Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer' on Sept. 10.
Brief Summary: This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Breast Cancer
Intervention:
DRUG: QL1706
QL1706 is a single bifunctional MabPair product consisting of two engineered monoclonal antibodies (anti-PD-1 and anti-CT...